William Blair Issues Optimistic Outlook for EW Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - William Blair raised their Q2 2026 earnings per share estimates for Edwards Lifesciences in a research note issued on Thursday, April 24th. William Blair analyst M. Andrew now expects that the medical research company will post earnings per share of $0.69 for the quarter, up from their prior estimate of $0.68. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. William Blair also issued estimates for Edwards Lifesciences' Q3 2026 earnings at $0.69 EPS and Q4 2026 earnings at $0.70 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $0.66 earnings per share.

A number of other brokerages have also recently issued reports on EW. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Robert W. Baird lifted their price target on Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a report on Thursday, April 24th. Truist Financial cut their price target on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Stock Performance

NYSE EW traded down $1.03 during trading hours on Friday, reaching $75.25. The company's stock had a trading volume of 1,400,453 shares, compared to its average volume of 4,980,719. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business has a 50-day simple moving average of $70.99 and a 200 day simple moving average of $71.20. Edwards Lifesciences has a 52 week low of $58.93 and a 52 week high of $95.25. The stock has a market cap of $44.24 billion, a PE ratio of 10.80, a PEG ratio of 4.82 and a beta of 1.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Crowley Wealth Management Inc. purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Vega Investment Solutions purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. Millstone Evans Group LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $29,000. Global X Japan Co. Ltd. raised its stake in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after purchasing an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC raised its stake in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after purchasing an additional 205 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 71,853 shares of company stock worth $5,163,062. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.